Seattle Children's Opens First CAR T-Cell Immunotherapy Trial in the U.S. for Children and Young Adults With Leukemia That Targets CD22 and CD19 Proteins Simultaneously
November 17, 2017
November 17, 2017
SEATTLE, Nov. 17 -- Seattle Children's Hospital issued the following news release:
Seattle Children's has opened the first chimeric antigen receptor (CAR) T-cell immunotherapy trial in the U.S. for children and young adults with relapsed or refractory CD19- and CD22-positive acute lymphoblastic leukemia (ALL) that will simultaneously attack two targets on cancer cells. With this more robust defense, researchers hope the new experimental therapy, first being investigated in the phase . . .
Seattle Children's has opened the first chimeric antigen receptor (CAR) T-cell immunotherapy trial in the U.S. for children and young adults with relapsed or refractory CD19- and CD22-positive acute lymphoblastic leukemia (ALL) that will simultaneously attack two targets on cancer cells. With this more robust defense, researchers hope the new experimental therapy, first being investigated in the phase . . .